INCOME STATEMENT (Quarterly GAAP In millions $) |
(Sep 30 2023) III. Quarter |
(Jun 30 2023) II. Quarter |
(Mar 31 2023) I. Quarter |
(Dec 31 2022) IV. Quarter |
(Sep 30 2022) III. Quarter |
Unrealized Gain Loss On Derivatives |
-0.16 |
0.40 |
-0.98 |
|
1.79 |
Interest and Fee Income, Loans and Leases |
8.61 |
9.28 |
9.26 |
|
8.50 |
Revenue From Contract With Customer Including Assessed Tax |
- |
- |
- |
|
- |
Pharmaceutical Development Revenue |
- |
0.18 |
0.12 |
|
5.11 |
Revenue Not From Contract With Customer Other |
0.04 |
- |
- |
|
- |
Other Revenue |
0.48 |
-0.36 |
1.02 |
|
-1.79 |
Total Revenue |
8.96 |
9.50 |
9.41 |
9.80 |
13.61 |
Cost of Revenues |
- |
- |
- |
0.47 |
- |
Provision for Other Credit Losses |
0.22 |
0.68 |
- |
- |
- |
Gross
Profit |
8.74 |
8.82 |
9.41 |
9.32 |
13.61 |
Selling, Administration, Marketing |
2.98 |
3.00 |
2.54 |
2.44 |
4.35 |
Depriciation & Amortization |
0.65 |
0.64 |
0.65 |
0.64 |
0.63 |
Research and Development Expense |
0.61 |
1.51 |
0.72 |
1.78 |
1.79 |
Exploration Abandonment and Impairment Expense |
- |
- |
- |
- |
- |
Other operatinig exp. /-income |
- |
- |
- |
7.95 |
0.08 |
Unusual Expense /-Income |
- |
- |
- |
- |
- |
Total operating costs including COS |
4.46 |
5.83 |
3.91 |
13.27 |
6.86 |
Operating income/-loss
|
4.50 |
3.67 |
5.50 |
-3.47 |
6.76 |
Other Deductions / - Income |
Interest expense |
0.18 |
0.36 |
0.18 |
0.10 |
0.08 |
Interest income |
- |
- |
- |
- |
- |
Net interest expense/-income |
0.18 |
0.36 |
0.18 |
0.10 |
0.08 |
Loss/ -Gain on Investment |
- |
- |
- |
-0.49 |
-0.01 |
Foreign Currency Transaction Gain, before Tax |
-0.08 |
0.32 |
0.19 |
-0.22 |
- |
Allowances, Health Care Trust Fund And Other |
- |
- |
- |
- |
- |
Unexpected (Gain) Loss |
- |
- |
- |
- |
- |
Other loss/ -income |
0.31 |
-2.40 |
0.61 |
1.51 |
-1.87 |
Total costs & expenses |
4.87 |
4.11 |
4.89 |
14.18 |
5.06 |
Income /-loss before income taxes |
4.09 |
5.39 |
4.53 |
-4.38 |
8.56 |
Income taxes expenses/-benefit |
-0.39 |
1.45 |
-0.11 |
-7.21 |
1.94 |
Income after income taxes |
4.47 |
3.93 |
4.64 |
2.83 |
6.62 |
Net income/-loss
of other equity |
- |
- |
- |
0.00 |
- |
Income/-loss
from cont. Ops. |
4.47 |
3.93 |
4.64 |
2.83 |
6.62 |
Accounting change |
- |
- |
- |
- |
- |
Discontinued operations |
- |
- |
- |
- |
- |
Extraordinary items |
- |
- |
- |
- |
- |
Net Income/-loss |
4.47 |
3.93 |
4.64 |
2.83 |
6.62 |
Noncontrolling interests |
- |
- |
- |
- |
- |
Prefered dividends |
- |
- |
- |
- |
- |
Other |
- |
- |
- |
- |
- |
Income/-loss to shareholder |
4.47 |
3.93 |
4.64 |
2.83 |
6.62 |
EBIT |
4.26 |
5.75 |
4.71 |
-4.28 |
8.64 |
EBITD |
4.92 |
6.39 |
5.36 |
-3.65 |
9.27 |
EBITDA |
4.92 |
6.39 |
3.91 |
-3.65 |
9.27 |